Significant boost to cash position by US $1.085m

Some significant good news regarding the company's cash position  in the half yearly:

Matters subsequent to the end of the financial half-year:
1. On 2 February 2021 the Group received a second grant of US$620,925 under the US Payroll Protection Program which is designed to protect employment during the COVID-19 pandemic.
2. On 25 February 2021 the Group agreed to receive US$465,843 from Inpixon (NASDAQ: INPX) as early settlement of the funds held back from the sale of nanotron Technologies GmbH net of working capital and other legal adjustments pursuant to the sale agreement.

That's an additional US$1.085m in the bank that should give the company a solid buffer from the need to raise cash any time soon.

Plenty of additional positives that I saw:
- Confirmation the sensor used for NanoDX is the final product
- Development of a laser-based sensor that has already hit key milestones and potentially ramp in FY22
- Abiomed forecasting a return to higher than previous run rate into FQ4 and FY22
- Several new sensor developments that should deliver non-recurring revenue
- Operational break-even level down to US$1.3m
- Overall positive signs regarding COVID and customer operations

Cheers